Chongqing Zhifei Bio Products Co., Ltd. was established in 2002. It is an international, industrial chain bio-high-tech enterprise integrating vaccines and biological products research and development, production, sales, promotion, distribution and import and export. In September 2010 Listed on the Shenzhen Stock Exchange, it has five wholly-owned subsidiaries and two shareholders, five wholly-owned subsidiaries and two shareholders, including Beijing Zhifei Green Bamboo Biopharma Co., Ltd. (hereinafter referred to as "Beijing Zhifei Green Bamboo"). ") and Anhui Zhifei Longkema Biopharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Zhifei Longkema") are high-tech enterprises.

The company's main human vaccines are the seven strategic emerging industries of the country, with broad development prospects. The independent products sold now include recombinant novel coronavirus protein vaccine (CHO cells) (Zhikewid®), Mycobacterium cow for injection (microka®), recombinant tuberculosis fusion protein (EC, Yika®), ACYW135 Group meningococcal polysaccharide vaccine (Mengwick®), Group A Group C Meningococcal polysaccharide binding vaccine (Mengnacon®), Type B influenzae B influenzae (Sifeibe®), etc. At the same time, the company is unified Sales of tetravalent human papillomavirus vaccine authorized by Merck (Saccharomyces cerevisiae), nine-valent human papillomavirus vaccine (Saccharomyces cerevisiae), oral pentavalent recombinant rotavirus live attenuated vaccine (Vero cells), 23-valent pneumococcal All imported vaccines on the market in mainland China, including polysaccharide vaccine, inactivated hepatitis A vaccine (human diploid cells). In addition, the company reached a cooperation with GSK in October 2023 on the supply, distribution and joint promotion of its recombinant shingles vaccine developed and produced.

Through the dual-wheel drive model of "technology & market", the company has continuously improved the industrial layout of "preventing before illness and treating existing illnesses", forming a good cycle mechanism for R&D, mutual promotion and mutual transformation of the market, and accelerated the development of vaccine products from R&D to The process of realizing market value conversion has gradually formed unique core competitiveness.

In terms of R&D, the company adopts the innovative strategy of "independent R&D as the main focus, cooperative R&D as the auxiliary, and investment incubation as the supplement", and has formed a highly qualified expert R&D team. It currently has more than 800 R&D personnel and has constructed a comprehensive three-dimensional R&D platform , has participated in more than 40 major projects including the Ministry of Science and Technology's 863 Program "Modern Medical Technology" project and the National New Drug Creation Major Project. The focus is on building three research and production bases in Beijing, Anhui and Chongqing, and multiple research and development centers have been set up in Beijing, Shanghai and other places. Currently, 29 projects under development have been announced. Eight product matrices, including meningitis vaccine matrix, pneumonia vaccine matrix, intestinal vaccine matrix, tuberculosis product matrix, multi-linked vaccine matrix, new emergencies vaccine matrix, adult vaccine matrix, upgraded vaccine matrix, etc., have been established, and the Polysaccharide and polysaccharide protein binding vaccine technology platform, gene recombination technology platform, inactivated vaccine technology platform, multi-link multivalent technology platform, mRNA vaccine technology platform, new adjuvant technology platform, human diploid cell line technology platform, adenovirus vector There are nine major technical platforms, including the vaccine technology platform and the outer membrane vesicle (OMV) technology platform.

In order to actively respond to the novel coronavirus pneumonia epidemic, the company cooperated with the Institute of Microbiology of the Chinese Academy of Sciences to develop a recombinant novel coronavirus protein vaccine (CHO cells) and promptly launched the development of the new coronavirus vaccine. The vaccine project was included in the "Public Safety Risk Prevention and Control of the Ministry of Science and Technology" and "Key special project of emergency technology equipment, obtained the Uzbekistan vaccine marketing license and my country's emergency use license in 2021. It was approved for conditional marketing in my country in March 2022. It has been vaccinated and used at home and abroad for more than 350 million doses, which is the case of the new crown epidemic. Make positive contributions to prevention and control. The company's recombinant tuberculosis fusion protein (EC) and mycobacterium cow (microcard) tuberculosis products were launched successively. EC is recommended by the World Health Organization (WHO) to diagnose tuberculosis infection, which can accurately screen the tuberculosis infection situation , has been included in the national medical insurance catalog; microcards not only have a good preventive effect on high-risk people with tuberculosis infection and latent infection of tuberculosis, but also have good effects on auxiliary treatment of active tuberculosis, which is of great significance to conquer tuberculosis. At the same time, the company has laid out the biomedical health industry, deepened its efforts in the fields of tumors, autoimmune diseases, metabolic diseases, neurodegenerative diseases, cardiovascular diseases, etc., and formed a three-dimensional development system of "prevention + diagnosis + treatment".

In terms of marketing promotion, the company has built a comprehensive and in-depth service network, which has provided more than 31 provinces, autonomous regions, and municipalities across the country, including more than 300 prefectures, more than 2,600 districts and counties, and more than 30,000 grassroots health service points (town vaccination sites) in 31 provinces, autonomous regions, and municipalities across the country, including more than 30,000 prefectures and cities, more than 2,600 districts and counties, and more than 30,000 grassroots health service points (town vaccination sites) in 31 provinces, autonomous regions, and municipalities across the country, including more than 30,000 cities and counties. , community outpatient clinics) provide continuous, fast and comprehensive high-quality services. The company has built a cold chain system that meets the requirements of the national GSP to achieve seamless cold chains for vaccine storage and transportation. It has delivered vaccine products to various disease prevention through a refrigerated truck with real-time temperature monitoring system and remote automatic monitoring alarms. Control Center.